Animal models for the study of. staphylococci. Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark

Similar documents
Antifungal PK/PD Made Simple. David Andes, MD University of Wisconsin

Pharmacokinetics as applied to in vitro and animal models

Pharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models

In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

Postantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

Ken Eguchi,* Katsunori Kanazawa, Yoshiro Eriguchi, and Yutaka Ueda. Dainippon Sumitomo Pharma Co., Ltd., Drug Research Division, Osaka, Japan

Polymicrobial Infection in Mice

Postantibiotic effect of roxithromycin, erytfaromycin, and clindamycin against selected Gram-positive bacteria and Haemophilus influenzae

Challenges in Antimicrobial Clinical Development. Axel Dalhoff & Heino Staß Institut für Klinische Pharmakologie Bayer AG, Wuppertal, D

Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models

Pharmacokinetics/Pharmacodynamics (PK/PD) of Peptide. Deformylase Inhibitor GSK against Streptococcus

In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium

ABC. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Volume 19 Number 18

PK-PD analysis and modelling

PK/PD als Instrument zur Steuerung der klinischen Entwicklung von Antibiotika

Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo

Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents

Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor

Biofilm Protocol Optimization For Pseudomonas aeruginosa. Introduction. Materials and Methods. Culture Media, Incubation Time, and Biofilm Measurement

Relation of Mucoid Growth of Staphylococcus aureus

ESCMID Online Lecture Library. by author

SKIN INFECTION OF RABBITS WITH HEMOLYTIC STREP- TOCOCCI ISOLATED FROM A PATIENT WITH ERYSIPELAS.

Establishing a Pseudomonas aeruginosa Biofilm in a Murine Model

Colistin: pharmacokinetics/pharmacodynamics:

Anti-staphylococcal activity of antibiotics in biofilm and host cell

Antistaphylococcal Activities of Teicoplanin and Vancomycin

FINAL REPORT Efficacy of a Cold Plasma System

21.4 Recombinant DNA technology Calculation worksheet. AQA Biology. Calculating the efficiency of DNA transfer during genetic engineering

Transmission Electron Microscopic Study of Antibiotic Action on Klebsiella pneumoniae Biofilm

obtained from the infected and treated tissues, Fleming's2 technic of hemolytic streptococcus B. Immediately following the infection, 1.0 ml.

Immobilization and Death of Bacteria by Flora Seal Microbial Sealant

Midori Green DNA Stain Safety Test Reports

Introduction. Abstract. Journal of Scientific and Innovative Research 2014; 3 (1): Available online at:

Comparison of the speed of kill of pathogenic bacteria using ACTICOAT and AQUACEL Ag analysed using Confocal Laser Scanning Microscopy

antigen." 2 Moreover, when mixed populations of normal and sensitive cells

Growth Promotion Test Guide for Media Used in Sterility Tests

Postantibiotic Effect of,3-lactam Antibiotics on Escherichia coli Evaluated by Bioluminescence Assay of Bacterial ATP

Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi

Pharmacokinetics of Cephalosporins in Normal and Septicemic Rabbits

In use test of a Washer-disinfector reprocessing of flexible endoscopes

Plasmid Midiprep Plus Purification Kit. Cat. # : DP01MD-P10/ DP01MD-P50 Size : 10/50 Reactions Store at RT For research use only

á61ñ MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS

Abstract. Mary Jane Ferraro, PhD, MPH Jana M. Swenson, MMSc

Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products

6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics

KILL-TIME STUDIES Antimicrobial Activity of EO H 2 O Using Clostridium difficile spores Test Solutions: Acidic H 2 O Submitted December 12, 2011

(From the Oscar Johnson Institute, Washington University School of Medicine, St. Louis)

Case. Case. Case. Case. Reference lab AST. Nelesh Govender, NICD 2013/03/08. Candida species: Antifungal susceptibility testing in 2013

TIDES 2014 GalNAc-siRNA with Enhanced Stabilization Chemistry: ESC-GalNAc-siRNA. May 14, 2014 Muthiah Manoharan

Effect of Thioglycolate on Phagocytic and Microbicidal Activities of Peritoneal Macrophages

Evaluation of a Novel Non-Sterile Glove Dispensing System Uyen Nguyen

Pharmacokinetics and Pharmacodynamics: Optimal Antimicrobial Therapy in the Intensive Care Unit

Administration of beta-lactams by prolonged and continuous infusion: when, how, and for which molecules?

Protocol for Albuwell M kit: Murine Microalbuminuria ELISA By Exocell Inc

Urine Monovette with Boric Acid

In vivo BrdU Incorporation Assay for Murine Hematopioetic Stem Cells Ningfei An, Yubin Kang *

JAC Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin

Lafayette, Indiana. Animals. Adult albino mice of the Purdue. Swiss and Rockland Swis strains were used. Toxin and antiserum. The toxin and antitoxin

ACCEPTED. Yanjun Li 1. M. Hong Nguyen 2,3,4. Harmut Derendorf 1. Shaoji Cheng 2. *Cornelius J. Clancy 2,3

Hollow Fiber System-TB 24 February 2014

IDEXX is an ISO certified facility. Gil Dichter World Wide Technical Support Manager

EZ-DNA. Instructions for Use. Genomic DNA Isolation Reagent. Product Description. Kit Reagent. Reagent Required But Not Supplied.

A General Protocol for GST Pull-down Lili Jing *

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group

EM021. Co-Trimoxazole Ezy MIC TM Strip (COT)( mcg/ml) (Trimethoprim/ Sulphamethoxazole) Antimicrobial Susceptibility Testing

Standardization of Antifungal Susceptibility Variables for a Semiautomated Methodology

in vivo-jetpei DNA & sirna delivery reagent

Regulatory hurdles and opportunities

Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products

8. Clinical Trial Assessment Phase II

Human IgG Antigen ELISA Kit

Modeling meropenem treatment, alone and in combination with daptomycin, for KPC- producing Klebsiella pneumoniae with unusually low carbapenem MICs.

Role of Serum in the Intracellular Killing of Staphylococci in Rabbit Monocytes

Antimicrobial Susceptibility Testing

Application Note. Yeast Analysis with a life - dead staining kit (Yeast control - viability)

1. Cross-linking and cell harvesting

Microbiological Standards for Reusable Plastic Containers within Produce Grower Facilities

Experimental Evaluation of Possible New Short-Term Drug Regimens for Treatment of Multibacillary Leprosy

Staphylococcus aureus bacteraemia Cases in Denmark 2016

Injectable modified release products

Methicillin resistant Staphylococcus aureus (MRSA)- Background and analysis

ISOLATION AND CHARACTERIZATION OF CLOSTRIDIUM CHAUVOEI STRAINS ISOLATED FROM CASES OF BLACKLEG IN CATTLE IN IRAN

BD GeneOhm MRSA ACP Lysis Kit

Final text for addition to The International Pharmacopoeia

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

ViraDuctin Lentivirus Transduction Kit

ELISA for Alpha-hemolysin (Hla) in Methicilin-resistant Staphylococcus aureus (MRSA) Varandt Y. Khodaverdian 1* and Menachem Shoham 2

The Most Probable Number Method and Its Use in QC Microbiology

Large Volume Serial Dilutions:

ISAH Warsaw, Poland Vol 2

Genomic Mini Versatile kit for genomic DNA purification from various sources. version 0517

Научно-исследовательский институт онкологии имени Н.Н. Петрова ОТДЕЛ КАНЦЕРОГЕНЕЗА И ОНКОГЕРОНТОЛОГИИ

CONTROL OF MICROBIAL GROWTH - DISINFECTANTS AND ANTISEPTICS

Transcription:

Animal models for the study of antibiotic PKPD against staphylococci Niels Frimodt Møller Professor, MD DMSc Dept. of Clinical Microbiology Hvidovre Hospital Denmark

Animal models for antibiotic acitivity against S. aureus General screening models: Peritonitis/sepsis mouse Thigh (myositis) mouse Wax moth larva (Galleria mellonella) Specialised infection models: Endocarditis rabbit, rat Osteomyelitis pig, rabbit, rat Skin infection mouse Pneumonia rat, mouse

Animal models for antibiotic PKPD acitivity against S. aureus General screening models: Peritonitis/sepsis mouse Thigh (myositis) mouse Wax moth larva (Galleria mellonella) Specialised infection models: Endocarditis rabbit, rat Osteomyelitis pig, rabbit, rat Skin infection mouse Pneumonia rat, mouse

AAC, 56: 568 73

AAC, 56: 568 73

Andes & Craig AAC 7 ECCMID 9 Abs 67

The mouse peritonitis model Intra- and extracellular activity of antibiotics against S. aureus Inoculation: Intraperitoneal injection of S.aureus 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

The mouse peritonitis model Intra- and extracellular activity of antibiotics against S. aureus Inoculation: Intraperitoneal injection of S.aureus peritonitis ( hr) 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

The mouse peritonitis model Electron microscopy of peritoneal fluid post infection with S. aureus Extracellular S. aureus 9 Intracellular S. aureus Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

The mouse peritonitis model Intra- and extracellular activity of antibiotics against S. aureus + Antibiotic treatment Intraperitoneal injection of S.aureus Subcutaneous injection of antibiotic 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

The mouse peritonitis model Intra- and extracellular activity of antibiotics against S. aureus + Sampling: Euthanasia Intraperitoneal injection of HBSS ( ml) and mix 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

The mouse peritonitis model Intra- and extracellular activity of antibiotics against S. aureus + Sampling: Euthanasia Intraperitoneal injection of HBSS ( ml) and mix Collection of peritoneal fluid through incision 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

Separation of intra- and extracellular bacteria A) Sampling of peritoneal fluid B) : dilution with HBSS C) Total colony count Division of sample into two equal fractions D) Division of sample into two equal fractions F) Centrifugation E) Admixture of lysostaphin G) Supernatant: Extracellular colony count H) Incubation 5 min K) Intracellular colony count J) Re-suspension in HO I) Centrifugation and re-suspension in HBSS. Four repetitions 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

Separation of intra- and extracellular bacteria A) Sampling of peritoneal fluid D) Division of sample into two equal fractions F) Centrifugation B) : dilution with HBSS C) Total colony count E) Admixture of lysostaphin Division of sample into two equal fractions Fraction A: Extracellular S. aureus estimated from supernatant after centrifugation G) Supernatant: Extracellular colony count H) Incubation 5 min K) Intracellular colony count J) Re-suspension in HO I) Centrifugation and re-suspension in HBSS. Four repetitions 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

Separation of intra- and extracellular bacteria A) Sampling of peritoneal fluid D) Division of sample into two equal fractions F) Centrifugation B) : dilution with HBSS C) Total colony count E) Admixture of lysostaphin Division of sample into two equal fractions Fraction A: Extracellular S. aureus estimated from supernatant after centrifugation G) Supernatant: Extracellular colony count K) Intracellular colony count J) Re-suspension in HO H) Incubation 5 min I) Centrifugation and re-suspension in HBSS. Four repetitions Fraction B: Intracellular S. aureus estimated after incubation with lysostaphin, lysostaphin wash-out, and lysis with H O 9 Sandberg et al., Antimicrob Agents Chemother (9) 53:874-883

Dose-response studies DICLOXACILLIN vs. S. aureus 4 IN VIVO 4 IN VITRO extracellular intracellular LOG (CFU) 4 4 4 mg/kg (log ) 4 4 4 mg/l (log ) log(cfu) = changes in colony counts compared to the original inoculum (treatment outcome) 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

Dose-response studies DICLOXACILLIN vs. S. aureus 4 IN VIVO 4 IN VITRO extracellular intracellular LOG (CFU) 4 4 4 mg/kg (log ) 4 4 4 mg/l (log ) Extracellular activity: dissimilar results were obtained in vitro and in vivo 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

Dose-response studies DICLOXACILLIN vs. S. aureus 4 IN VIVO 4 IN VITRO extracellular intracellular LOG (CFU) 4 4 4 mg/kg (log ) 4 4 4 mg/l (log ) Intracellular activity: similar results were obtained in vitro and in vivo 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

PK/PD studies: Dicloxacillin vs S. aureus LOG (CFU) -4hr EXTRACELLULAR R.4 INTRACELLULAR R.5 3 fauc/mic 4 hr 3 fauc/mic 4 hr No correlation between treatment outcome and the AUC/MIC index 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

PK/PD studies: Dicloxacillin vs S. aureus EXTRACELLULAR INTRACELLULAR LOG (CFU) 4hr 3 3 fc max /MIC fc max /MIC No correlation between treatment outcome and the Cmax /MIC index 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

PK/PD studies: Dicloxacillin vs S. aureus LOG (CFU) 4hr EXTRACELLULAR R.8 INTRACELLULAR R.89 3 ft>mic% 3 ft>mic% Correlation between treatment outcome and the T>MIC index 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

PK/PD studies: Dicloxacillin vs S. aureus LOG (CFU) 4hr EXTRACELLULAR R.8 INTRACELLULAR R.89 3 ft>mic% 3 ft>mic% T>MIC is the predicting PK/PD index both intra- and extracellularly 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

PK/PD studies: Dicloxacillin vs S. aureus LOG (CFU) 4hr EXTRACELLULAR R.8 INTRACELLULAR R.89 log reduction 3 ft>mic% 3 ft>mic% A reduction of logs was obtained intracellularly with optimal dosing 9 Sandberg et al., Antimicrob Agents Chemother () 54:39-4

Dose-response studies LINEZOLID vs. S. aureus 4 3 IN VIVO IN VITRO 4 3 intracellular extracellular log CFU 3 mg/kg (log ) 4 3 3 4 mg/l (log ) 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

Dose-response studies LINEZOLID vs. S. aureus 4 3 IN VIVO 4 3 IN VITRO intracellular extracellular log CFU 3 mg/kg (log ) 4 3 3 4 mg/l (log ) No decreased intracellular activity in vitro 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

Dose-response studies LINEZOLID vs. S. aureus 4 3 IN VIVO 4 3 IN VITRO intracellular extracellular log CFU 3 mg/kg (log ) 4 3 3 4 mg/l (log ) No reduction of the original intracellular inoculum in vivo 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

PK/PD studies: Linezolid vs S. aureus EXTRACELLULAR INTRACELLULAR log cfu 4hr - log CFU 4hr - fc max /MIC fc max /MIC No correlation between treatment outcome and the Cmax /MIC index 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

PK/PD studies: Linezolid vs S. aureus EXTRACELLULAR EXTRACELLULAR R =.55 R =.5 log cfu 4hr log cfu 4hr fauc 4h /MIC ft>mic% Both AUC and T>MIC correlated equally to the extracellular outcome 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

PK/PD studies: Linezolid vs S. aureus INTRACELLULAR INTRACELLULAR R =.9 R =.3 log cfu 4hr log cfu 4hr ft>mic% fauc 4h /MIC Poor correlation between PK/PD indices and the intracellular outcome 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

PK/PD studies: Linezolid vs S. aureus Conventional dose: 6 mg twice daily AUC/MIC = 8 EXTRACELLULAR INTRACELLULAR R =.55 R =.3 log cfu 4hr log cfu 4hr fauc 4h /MIC fauc 4h /MIC Acceptable extracellular effect but questionable intracellular effect with conventional dose 9 Sandberg et al., J. Antimicrob. Chemother () 65:96-973

Intracellular peritonitis mouse model: Fusidic acid 3 Total count Extracellular count 3 Intracellular count 3 log(cfu/ml) - -.5..5 3. 3.5 logauc/mic log(cfu/ml) - -.5..5 3. 3.5 logauc/mic log(cfu/ml) - -.5..5 3. 3.5 logauc/mic Sandberg et al. unpublished

Intracellular peritonitis mouse model: Fusidic acid log(cfu/ml) 3 - Total count log(cfu/ml) Extracellular count 3 - log(cfu/ml) Intracellular count 3 - - 5 5 T>MIC - 5 5 T>MIC - 5 5 T>MIC Sandberg et al. Unpublished

Conclusion S. aureus infection primarily intracellularly Still, antibiotic effect better (lower doses) in normal (non neutropenic) mice PKPD studies of antibiotics against S. aureus should include both intra and extracellular compartments Surprisingly, dicloxacillin best effect in vivo (vs. linezolid, fusidic acid, macrolides)